Verrica Pharmaceuticals Inc.
VRCA
$6.73
-$0.82-10.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.83M | 14.70M | 7.18M | 7.57M | 9.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.83M | 14.70M | 7.18M | 7.57M | 9.21M |
| Cost of Revenue | 10.17M | 9.69M | 11.21M | 14.58M | 18.38M |
| Gross Profit | 20.66M | 5.01M | -4.04M | -7.01M | -9.17M |
| SG&A Expenses | 36.98M | 43.66M | 51.33M | 58.82M | 65.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.15M | 53.36M | 62.55M | 73.40M | 84.32M |
| Operating Income | -16.32M | -38.65M | -55.37M | -65.84M | -75.11M |
| Income Before Tax | -26.01M | -48.60M | -65.99M | -76.58M | -84.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.01 | -48.60 | -65.99 | -76.58 | -84.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.01M | -48.60M | -65.99M | -76.58M | -84.99M |
| EBIT | -16.32M | -38.65M | -55.37M | -65.84M | -75.11M |
| EBITDA | -15.76M | -37.95M | -54.53M | -64.88M | -74.19M |
| EPS Basic | -3.44 | -8.30 | -12.01 | -15.36 | -18.27 |
| Normalized Basic EPS | -2.14 | -5.18 | -7.50 | -9.59 | -11.08 |
| EPS Diluted | -3.44 | -8.30 | -12.02 | -15.36 | -18.27 |
| Normalized Diluted EPS | -2.14 | -5.18 | -7.50 | -9.59 | -11.08 |
| Average Basic Shares Outstanding | 35.19M | 30.38M | 25.55M | 20.71M | 18.61M |
| Average Diluted Shares Outstanding | 35.20M | 30.39M | 25.55M | 20.71M | 18.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |